Group 1 - The core point of the article is that Jiet Biotech (SH 688026) held its 25th meeting of the fourth board of directors on November 21, 2025, via telecommunication, where it reviewed the proposal regarding not adjusting the conversion price of "Jiet Convertible Bonds" [1] - For the year 2024, Jiet Biotech's revenue composition is as follows: consumables account for 95.02% of total revenue, while other businesses account for 4.98% [1] - As of the report date, Jiet Biotech has a market capitalization of 2.4 billion yuan [1]

Company Overview - Weigao Blood Purification (SH 603014) held its 14th meeting of the second board of directors on September 15, 2025, to discuss the election of members for the remuneration and assessment committee [1] - As of the report date, Weigao Blood Purification has a market capitalization of 16.4 billion yuan [1] Revenue Composition - For the first half of 2025, the revenue composition of Weigao Blood Purification is as follows: consumables account for 77.55%, equipment accounts for 18.25%, other businesses account for 2.35%, and other categories account for 1.85% [1]

Group 1 - The core point of the article is that Jiet Biotech (SH 688026) held its 23rd meeting of the fourth board on August 28, 2025, to review the semi-annual evaluation report of the 2025 quality improvement and efficiency enhancement action plan [1] - For the fiscal year 2024, Jiet Biotech's revenue composition shows that consumables account for 95.02% of total revenue, while other businesses contribute 4.98% [1] - As of the report date, Jiet Biotech has a market capitalization of 2.7 billion yuan [1]

Group 1 - The company Jiet Biotech announced the resignation of its board secretary, Ge Jingbo, due to personal reasons, and he will no longer hold any position within the company after his resignation [2] - For the fiscal year 2024, Jiet Biotech's revenue composition is as follows: consumables account for 95.02% of total revenue, while other business segments contribute 4.98% [2]